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Abstract 
Accumulating evidence has indicated that inflammatory responses are important for 
cancer development.  Epidemiological studies have shown that regular use of 
non-steroidal anti-inflammatory drugs (NSAIDs) reduces the risk of colon cancer 
development.  Subsequently, mouse genetic studies have shown that COX-2, one of the 
target molecules of NSAIDs, and its downstream product, PGE2, play an important role in 
gastrointestinal tumorigenesis.  Bacterial infection stimulates the TLR/MyD88 pathway in 
tumor tissues, which leads to induction of COX-2 in stromal cells, including macrophages.  
Induction of COX-2/PGE2 pathway in tumor stroma is important for development and 
maintenance of an inflammatory microenvironment in the gastrointestinal tumors.  In such 
a microenvironment, tumor-associated macrophages express proinflammatory cytokines, 
including TNF- and IL-6, and these cytokines respectively activate the NF-B and Stat3 
transcription factors in epithelial cells, as well as in stromal cells.  Recent mouse studies 
have uncovered the role of such inflammatory network for the promotion of gastrointestinal 
tumor development.  Genetically engineered and chemically-induced mouse tumor models 
which mimic sporadic or inflammation-associated tumorigenesis were used in these studies.  
In this review article, we focus on mouse genetic studies using these tumor models, which 
contributed to elucidation of the molecular mechanisms associated with the inflammatory 
network in gastrointestinal tumors, and also discuss the role of each pathway in cancer 
development.  The involvement of immune cells such as macrophages, mast cells and 
regulatory T cells in tumor promotion is also discussed. 
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Introduction 
About 150 years ago, Rudolf Virchow described the presence of leukocytes in 
tumors, and hypothesized that the origin of cancer was at the site of chronic inflammation.  
It has been reported that chronic infections are associated with 15-20% of malignant 
cancers [1, 2].  The principal infectious agents are Helicobacter pylori, hepatitis B and C 
viruses, and the human papilloma virus, which are closely associated with gastric cancer, 
hepatocellular carcinoma, and cervical cancer, respectively.  Moreover, about 30% of all 
cancers have been attributed to smoking and 20% to obesity [3], and it has been shown that 
both tobacco smoke and obesity can trigger inflammatory responses in the lungs and liver, 
respectively, which promotes tumorigenesis [4, 5].  These results, together with those of 
other recent studies [reviewed in 6-8], indicate that inflammation plays an important role in 
promoting cancer development, and “tumor-promoting inflammation” is now included in 
the next generation of the criteria considered to be “hallmarks of cancer” [9].   
Epidemiological studies have revealed that regular use of non-steroidal 
anti-inflammatory drugs (NSAIDs) lowers the mortality rate from cancers in the 
gastrointestinal tract [10, 11].  The target molecules of NSAIDs are cyclooxygenase 
(COX)-1 and COX-2, and accumulating evidence has indicated that COX-2 and its 
downstream product, prostaglandin E2 (PGE2), play an important role in cancer 
development [12, 13].  On the other hand, proinflammatory cytokines are expressed in the 
tumor microenvironment, and such cytokine signaling is also important for cancer 
development through the activation of downstream transcription factors [6].  Among them, 
TNF- and IL-6 activate NF-B and Stat3, respectively, and both the TNF-/NF-B and 
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IL-6/Stat3 pathways have shown to be important for the development of 
inflammation-associated intestinal tumorigenesis [7, 8].  Moreover, NF-B induces the 
expression of COX-2, IL-6 and TNF-.  Accordingly, these signaling pathways construct 
an inflammatory network in the tumor microenvironment, which plays an important role in 
tumor promotion (Fig. 1).  In this review, we discuss the roles of these inflammatory 
pathways in gastrointestinal tumorigenesis, which have been identified by a number of 
mouse model studies as listed in Table 1. 
 
Mouse models of gastrointestinal cancer 
The roles of inflammatory responses in gastrointestinal cancers have been studied 
using several tumor mouse models (Table 1).  Apc716 knockout mice and ApcMin mice 
carry heterozygous truncation mutations at codon 716 and 850 of the mouse Apc gene, 
respectively, and somatic deletion of the wild-type Apc gene results in activation of 
Wnt/-catenin signaling, which causes tumor development in the entire intestinal tract [14, 
15].  Approximately 80% of colorectal cancers harbor APC gene mutations and half of the 
remainder have -catenin mutation, both of which activate Wnt/-catenin signaling [16-18].  
Thus, Apc716 and ApcMin mice recapitulate the molecular mechanism of sporadic colon 
cancer development.  Several other types of Apc mutant mice also develop intestinal 
polyposis (as described in this review and Table 1).   
On the other hand, inflammatory bowel diseases (IBD), including ulcerative colitis 
(UC) and Crohn’s disease (CD), are also risk factors for colorectal cancer [19, 20].  
IBD-related colon cancers are associated with severe inflammatory response, which is 
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important microenvironment required for inflammation-associated tumor development.  
The treatment of mice with a genotoxic chemical carcinogen, azoxymethane (AOM), 
followed by a non-genotoxic agent, dextran sodium sulfate (DSS), induces development of 
colitis-associated colon cancer (CAC) [21].  Mutations in the -catenin gene induced by 
AOM result in the activation of the Wnt/-catenin pathway, which is thought to trigger 
tumor initiation [22].  On the other hand, DSS induces colonic inflammation in rodents, 
which is required for tumor promotion.  Accordingly, the AOM/DSS model is a 
well-established and widely used mouse model for CAC development, and mimicks 
IBD-related colon cancer (Table 1).   Rag2 gene deficient mice lack functional 
lymphocytes, and are susceptible to infection-induced inflammation in the colon.  When 
Rag2-/- mice are infected with the enteric bacterial pathogen, Helicobacter hepaticus, mice 
rapidly develop CAC [23, 24].  This model system is also used for IBD-related colon 
cancer (Table 1). 
Activation of Wnt/-catenin signaling is found in approximately 30-50% of gastric 
cancers, suggesting a causal role of Wnt signaling in a subpopulation of gastric cancers [25, 
26].  On the other hand, Helicobacter pylori infection is an important risk factor for 
gastric cancer [27].  In H. pylori-associated gastritis, COX-2 expression is induced 
significantly, whereas its level decreases by H. pylori eradication [28, 29].  Two transgenic 
mouse strains, K19-Wnt1 mice expressing Wnt1 in the stomach, and K19-C2mE mice 
expressing COX-2 and mPGES-1, mimic Wnt activation and H. pylori-induced 
inflammation, respectively, in the stomach [26, 29-31].  Gan mice are compound 
transgenic mice with K19-Wnt1 and K19-C2mE, which express Wnt1, COX-2, and 
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mPGES-1 simultaneously in the gastric mucosa, resulting in activation of both Wnt 
signaling and the COX-2/PGE2 pathways as found in human gastric cancer.  Gan mice are 
thus used as a model of inflammation-associated gastric tumors [26, 30, 31] (Table 1).   
 
The COX-2/PGE2/EP2 pathway in gastrointestinal tumorigenesis 
It has been demonstrated that treatment of familial adenomatous polyposis (FAP) 
patients with NSAIDs results in significant regression of colon polyps [32].  Moreover, a 
large number of animal experiments have shown that treatment with NSAIDs suppressed 
chemical carcinogen-induced colon tumorigenesis [33].  As a target molecule of NSAIDs, 
inducible enzyme COX-2 plays an important role in inflammation and cancer, while 
COX-1 is expressed constitutively and functions as a house-keeping gene.  Importantly, 
disruption of the COX-2 gene in Apc716 mice and ApcMin mice resulted in a significant 
suppression of intestinal tumorigenesis, thus indicating an essential role of COX-2 in 
intestinal polyp development [34, 35].  Interestingly, disruption of the COX-1 gene also 
suppressed intestinal tumorigenesis [35].  It is possible that COX-1-derived prostaglandins 
are required for tumor cell proliferation during the initial stage when COX-2 expression is 
not yet induced [33].  Other lines of genetic evidence also support the role of the COX-2 
pathway in intestinal tumorigenesis.  Prostaglandins are catalyzed and inactivated by 
15-hydroxyprostaglandin dehydrogenase (15-PGDH).  The number of colon polyps in 
ApcMin mice was markedly increased when the 15-PGDH gene was disrupted, suggesting 
that PGE2 has a role in colon tumorigenesis [36].  Moreover, the transgenic expression of 
COX-2 in the mouse intestine accelerated chemical carcinogen-induced tumorigenesis [37].   
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COX-2 catalyzes synthesis of prostaglandin (PG)H2, which is then converted to 
PGE2.  There are four G protein-coupled receptors for PGE2; EP1, EP2, EP3, and EP4.  
Notably, disruption of the P2 gene caused significant suppression of intestinal polyposis in 
Apc716 mice, whereas suppression of EP1 or EP3 signaling did not affect tumorigenesis 
[38].  EP2 signaling increases the expression of VEGF and bFGF, which enhances 
angiogenesis in intestinal tumors [39].  Moreover, treatment of ApcMin mice with PGE2 
increased the development of intestinal tumors through activation of PPAR, which 
promotes survival of tumor cells [40].  Furthermore, PGE2 signaling through EP2 receptor 
has been shown to activate Wnt/-catenin signaling directly in colon cancer cells by 
suppression of -catenin phosphorylation [41].  Accordingly, it is possible that the 
COX-2/PGE2 pathway contributes to intestinal tumorigenesis through a variety of PGE2 
functions [12, 13] (Fig. 2).   
Microsomal PGE synthase-1 (mPGES-1) is an enzyme that converts PGH2 to PGE2, 
and expression of mPGES-1 is induced in gastric and colon cancers similar to COX-2 [42, 
43].  Notably, disruption of the mPGES-1 genes in Apc14 mice or AOM-treated mice 
resulted in a marked decrease in the PGE2 level in the intestinal mucosa, which led to a 
further significant suppression of intestinal tumorigenesis [44, 45].  Taken together, these 
results indicate that the simultaneous expression of COX-2 and mPGES-1 is required for 
intestinal tumorigenesis through the induction of PGE2 signaling. 
In gastric cancer tissues, induction of COX-2 is found in approximately 70% of 
cases [46, 47], and mPGES-1 expression is also induced [42], suggesting that the 
COX-2/PGE2 pathway is also important for gastric tumorigenesis.  In the K19-C2mE 
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transgenic mice, an increased PGE2 level causes inflammatory infiltration and metaplastic 
hyperplasia in the gastric mucosa [29].  Although Wnt activation alone is not sufficient for 
tumor development in K19-Wnt1 mice, Gan mice (compound mutants of K19-Wnt1 and 
K19-C2mE mice) develop inflammation-associated gastric tumors with 100% incidence 
[26], indicating that cooperation of the Wnt and PGE2 pathways can lead to gastric 
tumorigenesis.  Moreover, gastric inflammation and tumorigenesis were significantly 
suppressed in Gan mice when the mice were treated with a COX-2 inhibitor, celecoxib, or 
an EP4 receptor inhibitor [48, 49].  These results indicate that induction of 
COX-2/PGE2/EP4-induced inflammation is involved in the development of gastric cancer.  
Signaling through EP2 and EP4 both stimulate intracellular cyclic AMP signaling pathway. 
It is therefore possible that either EP2 or EP4 receptor signaling plays an important role in 
gastrointestinal tumorigenesis (Fig. 1). 
 
The TLR/MyD88 pathway for COX-2 induction in gastrointestinal tumors 
Expression of COX-2 and mPGES-1 is detected predominantly in stromal cells, 
including macrophages and fibroblasts, but not in the epithelial cells of mouse intestinal 
polyps, and the same is true for human colon polyps [36, 50-52].  Heterozygous mutations 
in the Lkb1, Smad4, or Cdx2 gene lead to the development of gastrointestinal hamartomas, 
which show distinct histological characteristics from dysplastic adenomas developed in Apc 
mutant mice [52-55].  Notably, expression of COX-2 and mPGES-1 is detected in the 
stromal cells, but not in tumor epithelial cells, in these models [56], thus indicating that the 
COX-2/PGE2 pathway is induced in the tumor stroma by a common mechanism, regardless 
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of the type of tumor.   
Several studies have suggested the commensal flora to play a role in the 
homeostasis of the intestinal mucosa.  Toll-like receptors (TLRs) are a family of 
pattern-recognition receptors that detect the molecular products of microorganisms.  
MyD88 is an adaptor molecule for TLR-mediated induction of inflammatory cytokines.  It 
has been shown that a disruption of the TLR2/4 or MyD88 genes in mice results in 
impaired mucosal repair from DSS-induced ulcers [57], suggesting that infectious 
stimulation through the TLR/MyD88 pathway is important for the regeneration process of 
injured mucosa.  Moreover, stromal macrophages are also required for mucosal repair of 
DSS-induced ulcers in the colon [58].  Accordingly, it is possible that stromal 
macrophages are activated by the TLR/MyD88 pathway.  In the case of intestinal 
tumorigenesis, cancer cells may use such a TLR/MyD88-induced regeneration system to 
increase their proliferation. 
The treatment of mice with DSS induces COX-2 expression and PGE2 production, 
predominantly in macrophages of the inflamed colon mucosa.  However, such COX-2 
induction is not found in the mice lacking the TLR4/MyD88 pathway [59], thus indicating 
the role of bacterial infection in inducing COX-2 expression in colitis tissues.  Importantly, 
AOM/DSS treatment-induced colon tumor development was dramatically suppressed in 
TLR4-/- mice [60], while exogenous administration of PGE2 promoted CAC development 
in the AOM/DSS-treated TLR4-/- mice [61].  Moreover, bone marrow chimera 
experiments indicated that TLR4 expression in the intestinal epithelial cells, but not in 
myeloid cells, is required for CAC development [62].  Taken together, these results 
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suggest that bacterial infection stimulates the TLR/MyD88 pathway in epithelial cells, 
which leads to activation of stromal macrophages, thus resulting in the induction of the 
COX-2/PGE2 pathway in the tumor stroma (Fig. 2).   
In contrast to the AOM/DSS model, ulcerative colitis is not associated with 
intestinal polyposis in the Apc mutant mice.  It is therefore possible that COX-2 
expression is induced by a different mechanism in sporadic colon cancer compared to 
IBD-related tumors.  However, ApcMin MyD88-/- mice showed significant suppression of 
intestinal polyposis with dramatically decreased mortality compared with control ApcMin 
MyD88+/+ mice [63, 64].  Moreover, induction of COX-2 expression was also suppressed 
in ApcMin MyD88-/- mouse intestinal tumors [63].  Bone marrow chimera experiments 
also indicated that MyD88 expression in the epithelial cells was important for intestinal 
tumorigenesis [64].  These results demonstrated that activation of the TLR/MyD88 
pathway in epithelial cells is also important for COX-2 expression in non-IBD colon cancer 
(Fig. 2).   
If bacterial infection is also required for COX-2 induction in the stomach, a low 
bacterial count due to the acidic environment in the stomach may protect against COX-2 
expression in tumorous lesions.  Therefore, it is possible that COX-2 induction through 
the TLR/MyD88 pathway is one of the mechanisms by which Helicobacter pylori infection 
promotes gastric cancer.   
It has also been shown that TLRs can be stimulated with endogenous ligands, 
including heat shock proteins and various products of the extracellular matrix [65].  
Accordingly, it is possible that tumor cell proliferation causes tissue damage, releasing 
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endogenous ligands for TLRs, thus resulting in their activation, which induces COX-2 
expression in stromal macrophages.  Such “cancer-induced inflammation” may be one of 
the mechanisms responsible for the generation of an inflammatory microenvironment, 
especially in cancers that are not associated with infection [65].   
 
The paradox of the COX-2 pathway in colitis-associated cancer 
Although COX-2 inhibition causes suppression of gastrointestinal tumorigenesis, 
treatment with NSAIDs or a COX-2 inhibitor exacerbates DSS-induced colon injury in 
rodent models [66].  Consistently, COX-2 gene knockout mice exposed to DSS showed 
exacerbated phenotypes, such as more severe inflammation, compared with wild-type mice 
[67].  One of the functions of PGE2 is to protect the gastrointestinal mucosa.  Therefore, 
COX-2 is important for mucosal protection and regeneration in the DSS-treated mouse 
colon.  Notably, treatment of COX-2 gene knockout mice with AOM/DSS resulted in a 
significant increase in tumors, with severe inflammatory responses [68, 69], which appears 
to be contradictory to the results showing that COX-2 gene disruption causes significant 
suppression of intestinal polyposis in Apc mutant mice [34, 35].  It is possible that in the 
case of severe ulcerative colitis, cytokine signaling is highly activated and may be sufficient 
for tumor promotion if the COX-2/PGE2 pathway is blocked (Fig. 2).   
 
The TNF-/NF-B pathway in gastrointestinal tumorigenesis 
TNF- is one of key regulators of inflammatory responses.  Although TNF was 
originally recognized as a tumor-necrotizing factor, accumulating evidence has indicated 
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that TNF- has tumor-promoting functions [70].  TNF- signaling activates NF-B, 
which further induces expression of inflammatory factors including COX-2, IL-6, IL-8 and 
TNF- itself (Fig. 1).  Several genetic studies have demonstrated a link between the 
TNF-/NF-B pathway and cancer development [71].   
Conditional disruption of the IKK gene in myeloid cells, which results in specific 
inhibition of NF-B, caused significant suppression of the tumor incidence in 
AOM/DSS-treated mice, and was associated with decreased expression of cytokines and 
COX-2 [72].  Conditional deletion of IKK in epithelial cells also suppressed 
AOM/DSS-induced tumorigenesis [72].  Similar results were found in TNF- receptor 
gene knockout mice. [73].  AOM/DSS treatment in mice lacking the TNF receptor p55 
(TNF-Rp55) gene resulted in attenuated tumor formation, with reduced inflammatory cell 
infiltration compared with wild-type mice.  Moreover, wild-type mice transplanted with 
TNF-Rp55-deficient bone marrow developed significantly fewer tumors after AOM/DSS 
treatment [73], indicating that TNF- stimulation of myeloid cells is important for 
tumorigenesis.  Accordingly, it is possible that the TNF--induced NF-B activation in 
myeloid cells is important for CAC development, and NF-B activation in epithelial cells 
also contributes to tumor formation (Fig. 2).   
It has also been shown that a disruption of a CCL2-specific receptor, CCR2, led to 
significantly decreased macrophage infiltration and lower tumor numbers when mice were 
treated with AOM/DSS [74].  CCL2 is a chemokine that is chemotactic for monocytes and 
macrophages [75].  Taken together, these findings indicate that the activation of NF-B in 
activated macrophages by TNF- in an autocrine or paracrine manner is important for 
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promotion of intestinal tumorigenesis (Fig. 2).  The inhibition of TNF- in Apc mutant 
mice by treatment with an anti-TNF- antibody also suppressed intestinal polyposis, with 
the suppression of angiogenesis [76].  Accordingly, it is possible that TNF-/NF-B 
activation is important in both IBD-related and sporadic colon carcinogenesis.   
An important role for the TNF-/NF-B pathway was also discovered in Mdr2 
knockout mice that develop inflammation-associated hepatocellular carcinoma (HCC) [77].  
In this mouse model, NF-B is activated in the liver by TNF- signaling, and inhibition of 
NF-B significantly suppressed development of HCC after 7 months of age [77].  On the 
other hand, preneoplastic dysplastic lesions in younger mice were not affected by NF-B 
inhibition.  It is possible that the TNF-/NF-B pathway is not required for the initiation 
step, but it does play a role in the promotion step of HCC development. 
The role of the TNF-/NF-B in gastric tumorigenesis in Gan mice has not yet been 
examined.  However, TNF- -/- K19-C2mE mice showed significant suppression of 
gastritis and hyperplasia compared with control K19-C2mE mice, although the 
COX-2/PGE2 pathway was still activated by transgenic expression of COX-2 and 
mPGES-1 [78].  It is thus conceivable that the TNF-/NF-B pathway is activated in 
PGE2-associated gastritis, and that this contributes to inflammation-associated gastric 
tumorigenesis. 
 
The IL-6/gp130/Stat3 pathway in gastrointestinal tumorigenesis 
One of the NF-B-inducible cytokines is IL-6, which is important for immune 
responses, cell survival, apoptosis, and proliferation [79].  The expression of IL-6 is often 
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upregulated in tumor tissues and the serum of human and mice with cancers, including 
colon cancer [80].  The IL-6 cytokine family signals through a common receptor, gp130, 
which activates Stat3 (Fig. 1).  Stat3 plays an important role in development of a variety 
of cancers, including CAC [81-84].  AOM/DSS-induced CAC development was 
significantly suppressed in IL-6-/- mice and also in conditional Stat3 knockout mice that 
lacked Stat3 in the intestinal epithelial cells through suppression of survival and 
proliferation [81, 82].  On the other hand, the number and size of AOM/DSS-induced 
colon tumors increased significantly in gp130757F/F mice, in which gp130-dependent Stat 
signaling is constitutively activated [81].  These results indicate that Stat3 activated in 
epithelial cells plays an important role in promotion of intestinal tumorigenesis (Fig. 2). 
It has been shown that gp130757F/F mice develop gastric tumors with abundant 
infiltration of inflammatory cells [85].  Moreover, heterozygous mutations of the Stat3 
gene in gp130757F/F mice reduced the incidence and multiplicity of gastric tumors, with 
suppression of inflammatory responses [86, 87].  These results indicate that Stat3 is also 
an important tumor-promoting factor in gastric tumorigenesis, and that it is activated by the 
inflammatory network of the tumor microenvironment.  TGF- signaling promotes 
epithelial differentiation, and thus, suppression of the TGF- signaling pathway has been 
thought to promote gastrointestinal tumorigenesis.  Notably, activation of Stat3 in 
gp130757F/F cells desensitizes to TGF- by inducing inhibitory Smad7.  This may be one of 
the mechanisms by which Stat3 promotes tumor formation [86].  IL-11 is another member 
of the IL-6 family cytokine and also signals through gp130.  Interestingly, disruption of 
the IL-11 co-receptor in 130757F/F mice significantly ablated gastric tumorigenesis [88].  
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Because IL-11 is upregulated in human and mouse gastric tumors, these results suggest that 
the IL-11/Stat3 pathway, together with IL-6/Stat3, promotes gastric tumorigenesis. 
 
Inflammatory cells that promote or suppress tumorigenesis 
The major source of inflammatory cytokines and prostaglandins in tumor tissues is 
the macrophages.  Tumor-associated macrophages (TAMs) have been shown to promote 
the progression and metastasis of cancer [89].  TAMs can be classified into several distinct 
groups by their functions, such as inducing inflammation, invasion, angiogenesis, or 
metastasis.  Macrophages are polarized to either the classical M1 type or the alternative 
M2 type, and it has been suggested that TAMs are polarized to M2 or M2-like types [90].  
It has been shown that CD4+ T cells regulate the polarization of macrophages to the M2 
type in mammary tumors [91].  It has recently been shown that COX-2 is important for the 
M2-polarization of TAMs in ApcMin mouse tumors [92].  Accordingly, it is possible that 
the COX-2/PGE2 pathway-induced inflammatory network is important for education of 
macrophages into the pro-tumorigenic M2 or M2-like types.  Importantly, depletion of 
functional macrophages in Apc716 mice by crossing them with op/op mutant mice resulted 
in significant suppression of intestinal polyposis [93].  Moreover, inhibition of 
macrophage recruitment in AOM/DSS-treated mice by CCL2 gene disruption resulted in 
suppression of colon tumor development [74].  Accordingly, macrophages play an 
important role for both sporadic and IBD-related intestinal tumorigenesis (Fig. 2).  In Gan 
mouse gastric tumors, macrophage depletion caused atrophic changes of the tumor cells 
and apoptosis of stromal cells, suggesting a role for macrophages in the maintenance of 
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tumor cells, as well as of tumor stromal cells [49].   
In the Apc468 mouse intestinal tumors, mast cells are preferentially enriched in the 
polyp tissues, and these mast cells express TNF- [76].  Notably, the depletion of mast 
cells in Apc468 mice by bone marrow transplantation from KitWsh/Wsh mice caused 
significant suppression of intestinal polyposis, with a decreased level of TNF- expression.  
It is therefore possible that both macrophages and mast cells are important components of 
the inflammatory network in the tumor microenvironment. 
Bone marrow transplantation from Rag2-/- mice did not affect the intestinal 
tumorigenesis in Apc468 mice [76].  Consistently, the gastritis phenotype was not altered 
in the K19-C2mE Rag2-/- mouse stomach [78].  These results indicate that lymphocytes 
are not required for construction of the inflammatory network and the promotion of 
tumorigenesis in the gastrointestinal tract.  Importantly, however, the adaptive transfer of 
CD4+ CD25+ regulatory T cells to ApcMin mice dramatically reduced the number of 
intestinal polyps, with induction of necrosis of tumor cells [94, 95].  Moreover, such 
regression of intestinal polyps was not found when CD4+ CD25+ cells were prepared from 
IL-10 -/- mice.   
The transfer of CD4+ CD25+ T cells to Helicobacter hepaticus-infected Rag2-/- 
mice, another IBD-related colon cancer model, resulted in suppression of colitis and tumor 
development, but IL-10-disrupted CD4+ CD25+ T cells could not suppress the development 
of CAC [23, 24].  IL-10 suppresses inflammatory responses, thus indicating that 
regulatory T cells expressing IL-10 suppress intestinal tumorigenesis by inhibiting the 
formation of the inflammatory network.  Although CD25+ Foxp3+ T cells are found in 
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ApcMin mouse polyp stroma, they no longer express IL-10, and instead switch to the 
production of IL-17 [95].  It is therefore possible that anti-inflammatory regulatory T cells 
(Foxp3+ IL-10+ IL-17-) shift to pro-inflammatory T cells (Foxp3+ IL-10- IL-17+) in polyp 
tissues [96].  Moreover, ablation of IL-17A in ApcMin mice significantly suppressed the 
development of intestinal polyps and inflammatory cytokine expression, indicating that 
T-cell-derived IL-17 plays an important role in intestinal tumorigenesis [97].   
 
Concluding remarks 
The development of the inflammatory network in tumor tissues and its possible 
roles are summarized in Figure 2.  Chronic infection or endogenous ligands derived from 
tumor cells stimulate the TLRs of epithelial cells, leading to the activation of MyD88.  
The activation of the epithelial TLR/MyD88 pathway further induces COX-2 expression 
and PGE2 production in stromal macrophages through the TNF-/NF-B pathway.  
Epidemiological studies and genetic experiments have demonstrated that COX-2 and its 
downstream product, PGE2, play an important role in gastrointestinal tumorigenesis.  
NF-B is activated by TNF- in tumor-associated macrophages, which further induces the 
expression of TNF-, IL-6 and COX-2.  TNF- in turn stimulates both tumor epithelial 
cells and stromal cells, activating NF-B in these cells, which promotes tumorigenesis.  
On the other hand, IL-6 activates Stat3 through gp130 in epithelial cells, thus leading to an 
increase in cell cycling and a decrease of apoptosis.  The induction of the COX-2/PGE2 
pathway is important for the development of such an inflammatory tumor 
microenvironment.  When the TNF-/NF-B and/or IL-6/Stat3 pathways are activated 
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beyond a threshold, they can promote tumorigenesis without the support of the 
COX-2/PGE2 pathway.  In the inflammatory microenvironment, not only TAMs, but also 
mast cells and IL-17-expressing T cells, infiltrate and contribute to tumor development.  
Therefore, targeting the inflammatory network in tumor tissues by inhibition of PGE2, 
NF-B, Stat3 or downstream pathways may provide an effective preventive or therapeutic 
strategy against gastrointestinal cancer. 
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Figure Legends 
Figure 1.  The interaction of the COX-2/PGE2, TNF-/NF-B, and IL-6/gp130/Stat3 
pathways in the inflammatory environment. 
 
Figure 2.  A schematic diagram of the inflammatory microenvironment in gastrointestinal 
tumor tissues.  Bacterial infection or endogenous ligand activates the TLR/MyD88 
pathway in epithelial cells, which further activate stromal macrophages inducing CCL2.  
In the activated macrophages, NF-B induces expression of COX-2, IL-6 and TNF- itself.  
COX-2/PGE2 pathway is important for construction and maintenance of the inflammatory 
network, and PGE2 accelerates angiogenesis, cell survival and Wnt activation.  TNF- 
activates NF-B in both epithelial cells and stromal macrophages, whereas IL-6 activates 
Stat3 in epithelial cells through gp130.  NF-B and Stat3 play important role in promotion 
of tumorigenesis through suppression of apoptosis and acceleration of cell cycle.  


Table 1. Mouse model studies to examine inflammatory network in gastrointestinal tumorigenesis 
tumor model mouse line crossed / treatment tumor phenotype changes references



















Ptgs2a knockout mice 
Ptgs1b, Ptgs2 knockout mice 
Hpgdc knockout mice 
Ptgs2 transgenic mice 
Ptger2d knockout mice 
 
PGE2 treatment 
Ptgese knockout mice 
Ptges knockout mice 
Myd88f knockout mice 
 
op/op (macrophage deficient) 
KitW/W (mast cell deficient) 
Rag2 -/- (lymphocytes deficient) 
anti-TNF- antibody 
CD4+ CD25+ T cell transfer 
 
Il17ag knockout mice 
suppression of intestinal polyposis 
suppression of intestinal polyposis 
increase of colon polyps 
increase of intestinal tumor  
suppression of intestinal polyposis 
  -inhibition of angiogenesis 
promotion of intestinal polyposis 
suppression of intestinal polyposis 
suppression of intestinal polyposis 
suppression of intestinal polyposis 
  -Epithelial expression of MyD88 is important. 
suppression of intestinal polyposis 
suppression of intestinal polyposis 
Not affected 
suppression of intestinal polyposis 
suppression of intestinal polyposis 
  -IL-10 expression in T cells is required. 


































-infected Rag2-/-  
Tlr4h knockout mice 
 
Ptgs2 knockout mice 
Ikbkbi conditional KO 
 
Tnfrsf1aj knockout mice 
 
Ccr2k knockout mice 
 
Il6l knockout mice 
gp130757F/F 
Stat3 conditional KO 
 
CD4+ CD25+ T cell transfer 
 
suppression of CAC development 
  -Epithelial expression of TLR4 is important. 
exacerbation of CAC development 
suppression of CAC development 
  -Epithelial and myeloid expression is important. 
suppression of CAC development 
  -Myeloid expression of TNF-Rp55 is important. 
suppression of CAC development 
  -Less macrophage infiltration 
suppression of CAC development 
suppression of CAC development 
suppression of CAC development 
  -Epithelial expression of Stat3 is important. 
suppression of CAC development 

























celecoxib, EP4 inhibitor 
clodronate liposome (macrophage 
deficient) 
Tnfm knockout mice 
Rag2 knockout mice 
Il11ra1n knockout mice 
gastric tumor development (Gan mice) 
suppression of gastric tumorigenesis 
atrophic changes of tumor cells 
 
suppression of gastritis/hyperplasia 
Not affected 
suppression of gastric tumorigenesis 







gene symbols uses are: aCOX-2, bCOX-1, c15-PGDH, dPGE2 receptor EP2, emPGES-1, fMyD88, gIL-17A, hTLR-4, iIKK, 
jTNF-Rp55, kCCR2, lIL-6, mTNF-, and nIL-11 receptor-. 
